Blackthorn Therapeutics Announces Close Of $76 Million Series B Financing

BlackThorn Therapeutics, a clinical-stage, neurobehavioral health company pioneering next-generation artificial intelligence (AI) technologies announced the close of its $76 million Series B financing. New investors include Polaris Partners, Premier Partners, Scripps Research, and Vertex Ventures HC. The four new investors joined the round with BlackThorn’s existing investors: Alexandria Venture Investments, Altitude Life Science Ventures, ARCH Venture Partners, Biomatics Capital, GV, Johnson & Johnson Innovation – JJDC, Inc., and Mercury Fund.

BlackThorn also announced two appointments to its executive management team: Jane Tiller, MBChB, FRCPsych, as chief medical officer, and Laura Hansen, Ph.D., as vice president, corporate affairs . . .